BioSpace News Archive

- New data from Phase 3 ADVANCE trial evaluating investigational medicine atogepant for the preventive treatment of migraine accepted for oral presentation - Presentation of real-world evidence assessing safety, tolerability, and potential benefits of treatment with BOTOX® (onabotulinumtoxinA) in combination with calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) for chronic migraine prevention - Oral presentation of Phase 3 data measuring the efficacy and sa

The immune system of human body depends on multiple checkpoints or immunological breaks, which avoid over-activation of the healthy cells or immune system.

The global equine healthcare market is rising due to horse racing trend, global development programs for animal health, and increasing incidence of equine infections.

Anti-neprilysin medications are used in the treatment of a wide range of health conditions including renal diseases, heart failure, and hypertension.

Cathepsin B is an important mediator of inflammation and programmed cell death in individual cells. It has a role in inducing cell dissolution and recycling of cellular organelles.

Plus Therapeutics, Inc., announced the appointment of five leading experts in the fields of neurological surgery and neuro-oncology to its Clinical Advisory Board.

At the General Meeting of the Company held at 11.00 a.m. on 2 October 2020, both of the resolutions were duly passed.

New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 75% of its enrollment target, which is 113 patients, for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The multinational human trial is being conducted in the U.S., Australia,

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced the pricing of an underwritten public offering of 3,225,806 shares of i